Vantage logo

The Cymabay recovery continues

Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.

Vantage logo

Novavax keeps investors waiting

Those wanting to see whether the US government was right to give Novavax $1.6bn two weeks ago will have to wait a little longer.